Nordson Corporation (NDSN) | The Buildout — AI Infrastructure
The Verdict
Nordson engineers and markets products and systems for precision dispensing, applying and controlling adhesives, coatings, polymers, sealants, biomaterials and other fluids, for testing and inspecting quality, and for treating and curing surfaces and medical products. In practice that means the machines, nozzles, valves and syringes that place a precise amount of fluid in a precise spot — underfill beneath a chip, adhesive on a package, coating on a circuit board — plus the X-ray, optical and acoustic inspection systems that confirm it landed correctly. Its Advanced Technology Solutions segment does that work inside semiconductor and printed-circuit-board production, including the advanced-packaging steps where dies are stacked, underfilled, encapsulated and inspected. That places Nordson beside the AI buildout rather than inside it: it sells picks-and-shovels tooling into packaging lines, and the company has not disclosed how much of its revenue is AI-specific.
| Market Cap | — |
| Revenue (TTM) | $3.0B |
| Revenue Growth | +7.0% |
| EBITDA Margin (TTM) | 31.8% |
| Net Debt | $1.7B |
| Earnings Beats | 5 of 7 |
| P/E (TTM) | — |
| EV/EBITDA (TTM) | — |
What We Like
- About 60% of the portfolio generates recurring revenue from aftermarket parts, consumables and services, and more than 50% now sits in growth end markets including semiconductor, electronics and medical (management, Q3 FY26).
- Advanced Technology Solutions grew 31% organically in Q3 FY26 to a record $220M, with segment EBITDA of $66M at a 30% margin, up 58% from $42M and 24% a year earlier.
- Backlog grew 35% year over year in Q3 FY26 with all three segments contributing; management says backlog turns over in about six months and roughly 80% of it converts.
- Cash of $113M against total debt of $1,814M at 31 July 2026; free cash flow converted at 144%, the fifth consecutive quarter above 100%.
- The quarterly dividend was raised 15% to $0.94 from $0.82 in August 2026, the 63rd consecutive year of annual increases.
What We’re Watching
- Fiscal 2027 ATS growth is guided to mid-single digits off an all-time peak — an explicit cap on the segment carrying the growth.
- North American chip-infrastructure spending is not yet in Nordson's orders: management said in Q3 FY26 that 'none of that has happened yet,' with a significant portion of current demand coming from Asia.
- Industrial Precision Solutions, which was about 45% of Q3 FY26 sales, grew 3% organically with systems demand 'stable but with limited growth,' and its EBITDA margin was flat at 35%.
- Incrementals landed just shy of 32% against a stated 35%–40% long-term target, in an environment of freight and commodity inflation.
- Full-year figures are the only guidance given: no Q4 sales or EPS range and no segment-level outlook, with the fiscal year ending in late October 2026.
The case looks stronger than it did two quarters ago. Nordson raised full-year guidance twice in two quarters, beat the high end of its own Q3 range on both sales and adjusted EPS, posted record quarterly sales in both Medical and Fluid Solutions and Advanced Technology Solutions, and accelerated backlog for a third consecutive quarter. What keeps it from being a clean story is that management itself is naming the ceiling: it guided fiscal 2027 ATS growth to mid-single digits off an all-time peak, said the North American chip-infrastructure opportunity is not yet in orders, and described its industrial optionality as 'singles, not home runs.' The open question is whether the order pace holds well enough to keep the backlog level high once the growth rate normalizes.
Earnings Beat
Fiscal Q3 2026 revenue was $817.7M, up 10% from a year earlier and 12% organically, with all three segments contributing. Gross margin was 55.5%, up from 54.8% in the year-ago quarter. The standout was Advanced Technology Solutions, which posted an all-time quarterly record of $220M in sales, up 31% organically, on semiconductor and broadening electronics demand.
| Metric | Q3 FY2026 | Q2 FY2026 | Q3 FY2025 | YoY |
|---|---|---|---|---|
| Revenue | $818M | $741M | $742M | +10.3% |
| Gross margin | 55.5% | 54.5% | 54.8% | +70bps |
| EBITDA | $260M | $234M | $226M | +15.1% |
| EPS | $2.73 | $2.09 | $2.21 | +23.6% |
| Backlog growth, year over year | +35% | +18% organically | n/a | — |
no real departure from what I would call normal order patterns… our backlog, generally speaking, turns over in about 6 months… no elongation in lead times.— Dan Hopgood, CFO, 2026-08-20
Management tone: Management was specific on demand and deliberately measured on the forward rate. The clearest shift is in Advanced Technology Solutions: the prior quarter described the cycle as 'early stages,' while the latest call said the company is at the 'peak of the cycle' — and, in the same answer, that it expects to build off that peak at a mid-single-digit rate. On backlog, the CFO said there has been no departure from normal order patterns and no elongation in lead times, and he attributed the guidance raise to ATS and medical rather than broad macro strength. On tariffs, management answered the margin question directly and then moved the conversation toward general inflation in freight and selected commodities.
Management Guidance
Management raised full-year FY2026 guidance to sales of $3.035–$3.075B and adjusted EPS of $11.80–$12.00, from $2.930–$3.010B and $11.30–$11.80 the prior quarter. The tax rate is guided to near 18% for the year, which the CFO called 'a good long-term expectation.' FX is assumed to hold at current levels, implying a neutral impact on the fourth quarter. Management expects a step-up in Q4 profitability from mix and operational initiatives, while flagging that year-over-year incrementals are harder because last year's Q4 was 'a bit of an outlier.' No Q4 quarterly sales or EPS range and no segment-level outlook were given. Separately, fiscal 2027 ATS growth is guided directionally to mid-single digits off an all-time peak.
Trajectory
The last three quarters show revenue stepping up: $669.5M in Q1 FY26, $740.8M in Q2 and $817.7M in Q3, against $615.4M, $682.9M and $741.5M in the same quarters a year earlier. Organic growth accelerated from 6.6% in Q2 to 12% in Q3, and EBITDA margin on an operating-income-plus-D&A basis moved from 30.3% to 31.5% to 31.8%. The mix is doing most of the work: ATS grew 31% organically in Q3 while IPS, about 45% of revenue, grew 3%, and MFS organic growth progressed from roughly 8% to 11%. Margins are being held rather than expanded — management says the IPS playbook is maintaining margin while maximizing growth — and incrementals came in just shy of 32% against a 35%–40% long-term target.
The Model
The model projects FY+1 revenue of $3,266M and EBITDA of $1,055M, a 32.3% EBITDA margin, and FY+2 revenue of $3,444M and EBITDA of $1,123M, a 32.6% margin. The FY+1 figure sits above management's FY2026 guidance range of $3.035–$3.075B and rests on the order book that grew 35%, its roughly six-month turnover, the guided mid-single-digit normalization in ATS, and continued medical growth. FY+2 adds $178M of revenue over FY+1 on a slightly higher margin, and depends on whether North American chip-infrastructure spending reaches Nordson's order book — which management says has not happened yet — and on capital deployment, with leverage at 1.7x and a stated focus on medical, test and inspection, and core bolt-ons.
| Metric | FY2025 | Next FY (E) | Following FY (E) |
|---|---|---|---|
| Revenue | $2.8B | $3.3B | $3.4B |
| YoY Growth | — | +17.0% | +5.5% |
| EBITDA | $862M | $1.1B | $1.1B |
| EBITDA Margin | 30.9% | 32.3% | 32.6% |
Projections are the median of 5 independent model runs. The model’s revenue sits 3.2% above analyst consensus.
Management raised full-year FY2026 guidance to sales of $3.035–$3.075B and adjusted EPS of $11.80–$12.00, from $2.930–$3.010B and $11.30–$11.80 the prior quarter. The tax rate is guided to near 18% for the year, which the CFO called 'a good long-term expectation.' FX is assumed to hold at current levels, implying a neutral impact on the fourth quarter. Management expects a step-up in Q4 profitability from mix and operational initiatives, while flagging that year-over-year incrementals are harder because last year's Q4 was 'a bit of an outlier.' No Q4 quarterly sales or EPS range and no segment-level outlook were given. Separately, fiscal 2027 ATS growth is guided directionally to mid-single digits off an all-time peak.
What Could Go Right — and Wrong
- Order entry keeps compounding, so the backlog level stays near its record even as the growth rate normalizes toward management's mid-single-digit guide.
- North American chip-infrastructure spending reaches Nordson's order book for the first time, adding a second demand region alongside Asia.
- Panel-level packaging becomes a quantified revenue line; the ASYMTEK Vantage XL launched at SEMICON Taiwan in August 2026 but carries no revenue figure yet.
- Medical and Fluid Solutions sustains its record run, holding the roughly 11% organic growth and 38% segment EBITDA margin it posted in Q3 FY26.
- Incrementals move back toward the stated 35%–40% long-term target from just shy of 32%, lifting EBITDA margin above current levels.
- ATS cools faster than the mid-single-digit fiscal 2027 guide; the segment was about 27% of Q3 FY26 revenue and roughly 63% of the year-over-year dollar increase (estimated from disclosed segment and total sales).
- IPS, about 45% of Q3 FY26 revenue, slips from 3% organic growth toward flat or negative as systems demand in industrial and agricultural markets stays limited.
- Inflation in freight and selected commodities keeps incrementals near 32%, and the IPS margin that has been held at 35% breaks lower.
- Backlog growth decelerates quickly given roughly six-month turnover and about 80% conversion; the 35% figure is a two-to-three-quarter statement, not a multi-year one.
- A raw-material or logistics shortage delays customer installations, which management has named as the thing it worries about, and Q4 comparatives are already flagged as harder.
Looking Ahead
The next twelve months turn on two things the company has already described. First, whether the order pace holds: backlog grew 35% but turns over in about six months with roughly 80% conversion, so the level depends on continued order entry rather than contracted revenue. Second, whether growth broadens geographically — management says North American chip-infrastructure investments have not reached Nordson's orders yet, while a significant portion of today's demand is being fulfilled in Asia. Guidance was raised twice in two quarters, the tax rate is now framed as a durable 18%, and leverage sits at 1.7x with management describing significant firepower for acquisitions in medical, test and inspection, and core bolt-ons.
- Fiscal Q4 2026Q4 and full-year results — Tests backlog conversion and the guided Q4 margin step-up.
- Fiscal 2027ATS growth rate — Management guides mid-single digits off an all-time peak.
- Fiscal 2027North American chip orders — Management says this demand has not reached the order book yet.
- No timing givenM&A announcement — Leverage 1.7x; stated focus on medical and test & inspection.
- Early stage; product launched 2026-08-25Panel-level packaging — ASYMTEK Vantage XL launched; revenue not quantified.
Financials
Annual Summary
| Metric | FY2024 | FY2025 | TTM | YoY |
|---|---|---|---|---|
| Revenue | $2.7B | $2.8B | $3.0B | +3.8% |
| Gross Margin | 55.3% | 55.1% | 55.3% | 17bps |
| EBITDA | $810M | $862M | $948M | +6.4% |
| EBITDA Margin | 30.1% | 30.9% | 31.8% | +77bps |
| Net Income | $467M | $484M | $555M | +3.7% |
| Free Cash Flow | $492M | $661M | $729M | — |
| Net Cash | — | — | — | — |
Key Ratios (Trailing)
- P/E TTM—
- EV/EBITDA TTM—
- EV/Revenue TTM—
- Price/FCF TTM—
- Gross Margin (TTM)55.3%
- EBITDA Margin (TTM)31.8%
- Net Margin (TTM)18.6%
- ROIC12.7%
- FCF Conversion76.8%
- SBC / Revenue0.4%
The Company
Nordson engineers, manufactures and markets differentiated products and systems used for precision dispensing, applying and controlling adhesives, coatings, polymers, sealants, biomaterials and other fluids, for testing and inspecting quality, and for treating and curing surfaces and various medical products, supported by direct global sales and service. The result is the machinery, nozzles, valves and single-use components that place a precise amount of fluid in a precise place — underfill beneath a chip, adhesive on a package, coating on a circuit board — plus the X-ray, optical, acoustic and bond-testing systems that verify it landed correctly. Revenue is reported in three segments: Industrial Precision Solutions, Medical and Fluid Solutions, and Advanced Technology Solutions.
The company runs a decentralized model built on two internal frameworks: the Ascend Strategy, which sets portfolio direction toward growth end markets and top products and customers, and the NBS Next growth framework, which management credits for lead-time reduction, on-time delivery and margin resilience. Principal manufacturing facilities are in the United States, China, Bulgaria, Germany, Ireland, Israel, Italy, Mexico, the Netherlands and the United Kingdom. About 60% of the portfolio generates recurring revenue from aftermarket parts, consumables and services, and more than 50% now sits in growth end markets including semiconductor, electronics and medical, with the remainder in more stable GDP-plus end markets.
Business Segments
Competitive Landscape
Competition in Nordson's equipment set is documented in two places, both from the other side of the relationship. Kulicke & Soffa lists Nordson among its major equipment competitors, alongside ASM Pacific Technology, Hesse, Han's Laser, BE Semiconductor, Hanwha Precision Machinery, Panasonic and Yamaha Robotics. Dover names Nordson within its Pumps & Process Solutions business. Nordson's own filings disclose no sole-source position: the 10-K's sole-source list is empty, and no named design win, long-term supply agreement or take-or-pay contract structure appears anywhere in the material. The company argues its lead-time advantage — cut from what used to be 16 to 18 weeks to under 7 to 8 weeks, and pushable to 4 — lets it gain share, and it says on-time delivery runs 80% to 95% in most businesses.
- Dover (DOV)Names Nordson within its Pumps & Process Solutions disclosure. Dover's Q2 2026 revenue rose 7% with book-to-bill of 1.06, and its data-center liquid-cooling heat exchangers had their best quarter ever with a plan to double capacity over 12 months.
- Kulicke and Soffa (KLIC)Lists Nordson among its major equipment competitors. KLIC guides TCB revenue of $150M–$200M in fiscal 2027, says it increased traditional wire-bonding capacity 4x from two quarters earlier, and notes it does not currently see a $450M run rate.
- Graco (GGG)Listed in the wiring map as a competitor in precision fluid dispensing; also appears there as a supplier of dispensing nozzles, valves and syringe barrels. Inferred, not disclosed.
- KLA (KLAC)Named in the inferred competitor set for inspection and dispensing overlap. Appears elsewhere in the same map as a reported customer. Not discussed by either company.
- Named together in the inferred competitor set covering optical inspection and advanced-packaging metrology. Not individually discussed.
Supply Chain
Nordson sits upstream of advanced-packaging and electronics assembly, selling dispensing, surface-treatment and inspection tools into foundries, memory makers and outsourced assembly houses. Its customer map is largely inferred, and no company in the neighbor set names Nordson by name.
More on NDSN: Earnings recap